AstraZeneca Pharma India Ltd. — Earnings Release 2025

Aug 8, 2024

==> picture [503 x 53] intentionally omitted <==

August 8, 2024

The Manager – Listing BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the unaudited financial results for the quarter ended June 30, 2024.

Thanking you,

For AstraZeneca Pharma India Limited

MANAS Digitally signed by MANASA RAMA Date: 2024.08.08 A RAMA 18:37:49 +05'30'

Manasa. R Company Secretary

==> picture [452 x 64] intentionally omitted <==

Press Release

==> picture [96 x 27] intentionally omitted <==

AstraZeneca Pharma India Limited Reports Strong Q1 Results, Achieving 31% Growth for Quarter ended June 30, 2024

Bangalore, August 8, 2024: AstraZeneca Pharma India Limited, a science-led biopharmaceu�cal company, is pleased to announce its financial results for the first quarter ended June 30, 2024. The Company reported strong financial performance, achieving a 31% increase in revenue compared to the same period last year. This growth is testament to our unwavering commitment to addressing the unmet medical needs of pa�ents in India and beyond.

Financial performance highlights for Q1’2024

• Revenue from Opera�on for the quarter stood at INR 3,875.2 million with substan�al 31% increase demonstra�ng Company’s focus on improving access to pa�ents.

• Profit before excep�onal item and tax is INR 424 million (11% of the total Income ) reflec�ng the Company’s efforts on driving profitable growth.

• Loss a�er excep�onal item and tax is INR 117.9 million ( -3% of total income ) due to booking of provisions associated with exit of factory site announced in this quarter.

Dr. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " We are pleased to report a strong financial performance this quarter. It reflects our con�nuous endeavour of harnessing science and commitment to bringing innova�ve medicines faster to India. We are focused on our ambi�on to ensure our therapies reach the pa�ents who need them the most and are constantly working to tailor sustainable programs focused on early diagnosis and improved access to meet local needs by collabora�ng with healthcare systems, payers, policymakers, and non-government organiza�ons."

Bhavana Agrawal, Chief Finance Officer, added, "It’s a strong start of the year with 31% revenue growth and double-digit profit margin (before excep�onal item and tax). The results are an outcome of Company’s focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years. We are con�nuously pushing the boundaries of science and are well posi�oned for consistent value crea�on for our customers and shareholders.”

AstraZeneca India con�nues to advance its mission of transforming the future of healthcare by unlocking the power of science for the benefit of people, society, and the planet. The Company's commitment to innova�on is reflected in its strong pipeline progress, reinforcing its posi�on as a key player in the healthcare industry.

Key milestones achieved for Q1 ’2024:

• Partnered with Vaayu Chest & Sleep Center to elevate the standard of respiratory care for severe asthma patients by setting up Center of Excellence (COE) in Bengaluru.

Recogni�ons:

• Recognized as one of "India's Best Organizations in Innovation" by ET Now

• Awarded ‘Pharma InHouse Legal Team of the Year’ at the 13[th] Annual Legal Era - Indian Legal Awards 2023-24

• Amarpreet Kaur Ahuja, Country HR Director, was featured among “The Powerhouses of Indian HR: Women Driving Change and Innovation” by Indian Conventions.

==> picture [96 x 27] intentionally omitted <==

About AstraZeneca:

AstraZeneca is a global, science-led biopharmaceu�cal company that focuses on the discovery, development and commercialisa�on of prescrip�on medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Diseases. AstraZeneca operates in over 100 countries and its innova�ve medicines are used by millions of pa�ents worldwide. Established in 1979, it is headquartered at Bengaluru, Karnataka and has a workforce of over 900 employees across the country commi�ed to deliver great medicines to pa�ents through innova�ve science and global excellence in development and commercializa�on. For more informa�on, please visit our website: www.astrazeneca.com/india, or connect with us on LinkedIn and X.com.